CBD: start with the studied preparation

These CBD trials used synthetic capsules, an oil-based supplement or a pharmaceutical oral solution, in different populations. The shared ingredient name does not establish retail interchangeability.

In a short adaptive trial, 82 participants with at least moderate cannabis use disorder who intended to stop cannabis use were randomized. Participants used cannabis with tobacco, and all groups received motivational interviewing. Some CBD trial groups met the paper’s Bayesian decision criterion for cannabis-use measures. This was dose finding within that combined setting, not a definitive CBD-alone treatment result.

One abstinence interval crossed zero despite meeting the trial’s Bayesian decision rule. Decision probabilities and intervals answer different questions; neither means simply “works.”

A small crossover study tested acute isolated CBD in a driving simulator. Some comparisons met its prespecified non-inferiority rule; four were inconclusive. Inconclusive does not mean equivalent, and a simulator result does not grant permission to drive or cover THC mixtures, chronic use or interacting medicines.

In a trial of autistic boys aged 7–14 with persistent moderate-to-severe problem behaviors, pharmaceutical CBD did not significantly outperform placebo on the primary repetitive-behavior total score. Other primary between-treatment measures were also nonsignificant. Within-group improvement does not replace the randomized comparison. The paper reports 44 randomized and 39 analyzed, but its completion and withdrawal descriptions conflict; those counts remain unresolved.

The cannabis-use trial reported no severe adverse events, while the autism trial reported events during CBD, placebo and washout. These are limited trial observations, not proof of long-term safety. The cannabis-use trial had public research funding and disclosed an author’s outside industry fees; the autism trial disclosed foundation/NIH support and donated drug and placebo.

Abstract-limited example: the Dravet syndrome trial studied adjunctive CBD oral solution in children and young adults with drug-resistant seizures. Its abstract reports a primary convulsive-seizure-frequency difference and a nonsignificant comparison of participants with at least a 50% reduction in convulsive seizures, as well as more adverse effects with CBD. Full methods, detailed harms and disclosures were not accessible for this packet. This example cannot support a complete review or retail equivalence claim.